1. Home
  2. RNAZ vs BEAT Comparison

RNAZ vs BEAT Comparison

Compare RNAZ & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

SELL

Current Price

$1.40

Market Cap

27.9M

Sector

Health Care

ML Signal

SELL

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

SELL

Current Price

$0.37

Market Cap

22.7M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
RNAZ
BEAT
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
22.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
RNAZ
BEAT
Price
$1.40
$0.37
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $3.13
AVG Volume (30 Days)
17.7K
★ 1.1M
Earning Date
08-14-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 15.07
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,197.12
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$0.36
52 Week High
$12.60
$4.00

Technical Indicators

Market Signals
Indicator
RNAZ
BEAT
Relative Strength Index (RSI) 31.10 40.42
Support Level N/A N/A
Resistance Level $1.93 $0.52
Average True Range (ATR) 0.15 0.05
MACD -0.02 -0.01
Stochastic Oscillator 0.00 1.41

Price Performance

Historical Comparison
RNAZ
BEAT

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

Share on Social Networks: